Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Alphabet Inc Class A — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.57 (market cap $5.07B), while Alphabet Inc Class A trades at $344.04 (market cap $4.20T). The key difference: Alphabet Inc Class A is far larger — about 828.4× ACADIA Pharmaceuticals Inc.'s market cap, and Alphabet Inc Class A pays a 0.26% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | GOOGL | |
|---|---|---|
Market Cap | $5.07B | $4.20T |
Sector | Health | Media |
52-Week High | $29.41 | $402.62 |
52-Week Low | $20.06 | $199.32 |
Enterprise Value | $4.19B | $4.09T |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
Alphabet (GOOGL) trades at $344.00, down 3.78% on the day, with technical indicators showing bearish momentum below key resistance at $347. Fundamentally, the company demonstrates strong profitability with 54.77% net income margin and consistent earnings beats, though valuation multiples remain elevated with P/E at 17.25. Recent developments include YouTube subscription price increases and continued AI infrastructure investments.
The stock presents a compelling long-term opportunity given strong analyst consensus (85% buy ratings) and $426.28 price target, representing 24% upside. Key risks include antitrust scrutiny and tech sector rotation pressures, but Alphabet's AI leadership and diversified revenue streams support growth prospects despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
